NEW YORK (GenomeWeb) – Cepheid has launched a CE marked bladder cancer test that is currently commercially available in Germany and will launch throughout Europe in the coming months.

The Xpert Bladder Cancer Monitor test runs on the firm's GeneXpert molecular diagnostics system. It has about a 94 percent negative predictive value, so could be particularly useful in more confidently ruling out bladder cancer and reducing the need for more invasive testing, Cepheid said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.